Physician profile
Naveed Jan
NPI 1285743542
$16,577.02
in general payments reported to CMS, 2019-2025
81 companies · $1,881 in 2025
The $1,881 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,598 · 2020: $2,074 · 2021: $2,515 · 2022: $1,987 · 2023: $2,472 · 2024: $2,050 · 2025: $1,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,019 · Education: $218 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,018.77 |
| Education | $217.68 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,227.44 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,462.65 | 2019-2025 | Lynparza, Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $1,349.12 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $922.43 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Incyte Corporation | $748.87 | 2019-2025 | Jakafi |
| Amgen INC. | $739.63 | 2019-2023 | Lumakras, Blincyto, Kyprolis |
| Janssen Biotech, INC. | $708.60 | 2019-2025 | Akeega, Balversa, Erleada |
| Daiichi Sankyo INC. | $519.56 | 2020-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $470.43 | 2019-2025 | Polivy, Venclexta, Lunsumio |
| Glaxosmithkline, LLC. | $469.93 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Astellas Pharma US INC | $397.30 | 2019-2025 | Padcev, Vyloy |
| Gilead Sciences, INC. | $377.60 | 2019-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $322.87 | 2019-2025 | |
| Abbvie INC. | $307.78 | 2019-2025 | |
| Pfizer INC. | $303.61 | 2019-2025 |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveed Jan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.